Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Martin O. Bergo, … , Patrick J. Casey, Stephen G. Young
Martin O. Bergo, … , Patrick J. Casey, Stephen G. Young
Published February 15, 2004
Citation Information: J Clin Invest. 2004;113(4):539-550. https://doi.org/10.1172/JCI18829.
View: Text | PDF
Article Cell biology

Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf

  • Text
  • PDF
Abstract

Isoprenylcysteine carboxyl methyltransferase (Icmt) methylates the carboxyl-terminal isoprenylcysteine of CAAX proteins (e.g., Ras and Rho proteins). In the case of the Ras proteins, carboxyl methylation is important for targeting of the proteins to the plasma membrane. We hypothesized that a knockout of Icmt would reduce the ability of cells to be transformed by K-Ras. Fibroblasts harboring a floxed Icmt allele and expressing activated K-Ras (K-Ras-Icmtflx/flx) were treated with Cre-adenovirus, producing K-Ras-IcmtΔ/Δ fibroblasts. Inactivation of Icmt inhibited cell growth and K-Ras–induced oncogenic transformation, both in soft agar assays and in a nude mice model. The inactivation of Icmt did not affect growth factor–stimulated phosphorylation of Erk1/2 or Akt1. However, levels of RhoA were greatly reduced as a consequence of accelerated protein turnover. In addition, there was a large Ras/Erk1/2-dependent increase in p21Cip1, which was probably a consequence of the reduced levels of RhoA. Deletion of p21Cip1 restored the ability of K-Ras-IcmtΔ/Δ fibroblasts to grow in soft agar. The effect of inactivating Icmt was not limited to the inhibition of K-Ras–induced transformation: inactivation of Icmt blocked transformation by an oncogenic form of B-Raf (V599E). These studies identify Icmt as a potential target for reducing the growth of K-Ras– and B-Raf–induced malignancies.

Authors

Martin O. Bergo, Bryant J. Gavino, Christine Hong, Anne P. Beigneux, Martin McMahon, Patrick J. Casey, Stephen G. Young

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Growth factor-stimulated Erk1/2 and Akt1 phosphorylation in Icmt-deficie...
Growth factor-stimulated Erk1/2 and Akt1 phosphorylation in Icmt-deficient fibroblasts. (a) Nontransfected Icmtflx/flx and the derivative IcmtΔ/Δ fibroblasts were seeded at equal density and serum-starved overnight as described in the Methods section. Serum-containing medium was then added to the cells. Cells were harvested at the indicated time points and analyzed by immunoblotting with antibodies against phosphorylated Erk1/2 (p-Erk1/2), phosphorylated Akt1 (p-Akt1), and total Erk1/2. (b) Icmtflx/flx and the derivative IcmtΔ/Δ fibroblasts were seeded at equal density and serum-starved overnight. Medium (0.5% serum) supplemented with EGF (50 ng/ml) was added to the cells. Cells were harvested at the indicated time points and analyzed by immunoblotting with antibodies against p-Erk1/2 and total Erk1/2.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts